These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31399271)

  • 1. A community outreach intervention to link individuals with opioid use disorders to medication-assisted treatment.
    Scott CK; Dennis ML; Grella CE; Kurz R; Sumpter J; Nicholson L; Funk RR
    J Subst Abuse Treat; 2020 Jan; 108():75-81. PubMed ID: 31399271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid recovery initiation: Pilot test of a peer outreach and modified Recovery Management Checkup intervention for out-of-treatment opioid users.
    Scott CK; Grella CE; Nicholson L; Dennis ML
    J Subst Abuse Treat; 2018 Mar; 86():30-35. PubMed ID: 29415848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
    Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
    J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction to the special issue on innovative interventions and approaches to expand medication assisted treatment: Seizing research opportunities made available by the opioid STR program.
    Watson DP; Andraka-Christou B; Clarke T; Wiegandt J
    J Subst Abuse Treat; 2020 Jan; 108():1-3. PubMed ID: 31668689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 6. Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.
    Cochran G; Cole ES; Warwick J; Donohue JM; Gordon AJ; Gellad WF; Bear T; Kelley D; DiDomenico E; Pringle J
    Addict Sci Clin Pract; 2019 Aug; 14(1):25. PubMed ID: 31366408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year.
    Pro G; Utter J; Haberstroh S; Baldwin JA
    Drug Alcohol Depend; 2020 Apr; 209():107952. PubMed ID: 32172130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
    Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
    J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
    Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
    Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
    Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
    J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue.
    McElrath K; Joseph H
    Subst Use Misuse; 2018 Jan; 53(2):177-180. PubMed ID: 29220615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department.
    Martin A; Butler K; Chavez T; Herring A; Wakeman S; Hayes BD; Raja A
    West J Emerg Med; 2020 Nov; 21(6):257-263. PubMed ID: 33207174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the needs of front-line providers in addressing the opioid crisis in South Carolina.
    Moreland A; McCauley J; Barth K; Bogdon C; Killeen T; Haynes L; Jennings L; Guille C; Goldsby S; Brady K
    J Subst Abuse Treat; 2020 Jan; 108():4-8. PubMed ID: 31303360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.
    Trigg BG; Dickman SL
    Subst Abus; 2012; 33(1):76-84. PubMed ID: 22263716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.